lazertinib,amivantamab
janssen,yuhan corp
['lcsm,(-blcsm)', 'amivantamab', 'biomarker', 'lazertinib']
#asco23 #lcsm discussing biomarker validation (c-d) chrisalis-2 met+ by ihc may be a predictive biomarker for response to amivantamab plus lazertinib in the post-osi, chemotherapy-na ve setting. 
MD PhD, lung oncologist & researcher @IEOufficiale; @myESMO Communication Committee Chair; #LungCancer Molecular target-believer #LCSM